Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 20:04:38时区推断·⟳ 抓取 20:09:29·⚡ 决策 08-04 22:26:27 +2h16m·84.0 天前
Nuvation Bio宣布将在肺癌会议展示IBTROZI亚组分析
本次只是宣布9月和10月会议将展示既有TRUST-I/TRUST-II亚组分析，未披露新的疗效、安全性或商业化增量数据。
📄 原文Investing.com↗ 原文
Nuvation Bio to present subgroup analyses at lung cancer conferences
BofA says this memory stock could double. Here are 5 reasons why NEW YORK - Nuvation Bio Inc. (NYSE:NUVB) announced Mon…
不做 Nuvation Bio（NUVB.US）
只是未来医学会议展示安排，未披露新增临床结果、获批、销售或患者池变化，方向和量级都不足以形成可回测交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 low · price-in 风险 medium ↗
关键理由
- 本次只是宣布9月和10月会议将展示既有TRUST-I/TRUST-II亚组分析，未披露新的疗效、安全性或商业化增量数据。
- IBTROZI已于2025年6月获FDA批准，当前稿件对收入、适应症、支付或患者池没有新增可量化改变。
主要风险
- 若会议正式披露显著优于预期的新疗效数据或商业化指引，应由新信号重新研判。
原文全文
展开原文 · 2,049 字
BofA says this memory stock could double. Here are 5 reasons why
NEW YORK - Nuvation Bio Inc. (NYSE:NUVB) announced Monday that new analyses of Phase 2 TRUST-I and TRUST-II data will be presented at two upcoming medical conferences in September and October, according to a press release statement.
The company will present findings at the IASLC 2026 World Conference on Lung Cancer from September 12-15 in Seoul, South Korea, and at the European Society of Medical Oncology Congress from October 23-27 in Madrid, Spain. The presentations will examine the efficacy and safety of IBTROZI (taletrectinib) for treating adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer across different patient subgroups.
At the World Conference on Lung Cancer, Dr. Hidetoshi Hayashi from Kindai University Faculty of Medicine will present results on September 15. At the ESMO Congress, Dr. Maurice Pérol from Léon Bérard Cancer Center will present updated efficacy and safety data for patients previously treated with entrectinib on October 26.
The FDA approved taletrectinib on June 11, 2025, for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC, following Priority Review and Breakthrough Therapy designations.
The TRUST clinical program comprises three registrational studies. TRUST-I and TRUST-II are Phase 2 single-arm studies evaluating IBTROZI in China (173 patients) and globally (189 patients), respectively. TRUST-IV is a Phase 3 placebo-controlled study for adjuvant treatment of resected early-stage ROS1-positive NSCLC, expected to enroll approximately 180 patients with primary completion estimated in 2030.
Approximately 2% of NSCLC patients have ROS1-positive disease. About 35% of patients newly diagnosed with metastatic ROS1-positive NSCLC have brain metastases, and approximately 50% of previously treated patients develop central nervous system metastases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW YORK - Nuvation Bio Inc. (NYSE:NUVB) announced Monday that new analyses of Phase 2 TRUST-I and TRUST-II data will be presented at two upcoming medical conferences in September and October, according to a press release statement.
The company will present findings at the IASLC 2026 World Conference on Lung Cancer from September 12-15 in Seoul, South Korea, and at the European Society of Medical Oncology Congress from October 23-27 in Madrid, Spain. The presentations will examine the efficacy and safety of IBTROZI (taletrectinib) for treating adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer across different patient subgroups.
At the World Conference on Lung Cancer, Dr. Hidetoshi Hayashi from Kindai University Faculty of Medicine will present results on September 15. At the ESMO Congress, Dr. Maurice Pérol from Léon Bérard Cancer Center will present updated efficacy and safety data for patients previously treated with entrectinib on October 26.
The FDA approved taletrectinib on June 11, 2025, for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC, following Priority Review and Breakthrough Therapy designations.
The TRUST clinical program comprises three registrational studies. TRUST-I and TRUST-II are Phase 2 single-arm studies evaluating IBTROZI in China (173 patients) and globally (189 patients), respectively. TRUST-IV is a Phase 3 placebo-controlled study for adjuvant treatment of resected early-stage ROS1-positive NSCLC, expected to enroll approximately 180 patients with primary completion estimated in 2030.
Approximately 2% of NSCLC patients have ROS1-positive disease. About 35% of patients newly diagnosed with metastatic ROS1-positive NSCLC have brain metastases, and approximately 50% of previously treated patients develop central nervous system metastases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。